Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiHA-loaded donor dendritic cell vaccination after allogeneic stem cell transplantation
NL-OMON40014Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2013
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of MiHA mRNA-electroporated donor dendritic cell vaccine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 4 more, sponsored by Radboud University Medical Center. Primary endpoints: Safety, Toxicity and 2 more. Planned start Aug 2013; status: not yet recruiting.
02
Drugs
MiHA mRNA-electroporated donor dendritic cell vaccine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON40014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40014.